This book focuses on the coronary bioresorbable scaffold, a new interventional treatment for coronary artery disease, differentiated from a permanent metallic stent. The book provides an overview of the technology including non-clinical studies and clinical evidences in order to help clinicians understand the appropriate application of the technology and the optimal techniques of implantation. It covers the basics of bioresorbable scaffolds; bench test results; preclinical studies; clinical evidences; and tips and tricks of implantation.
Section 1: Introduction 1.1- Early development of bioresorbable scaffold
Section 2: Principles of bioresorption, vascular application 2.1- Degradable,
biodegradable and bioresorbable polymers for time-limited therapy 2.2- Lactic
acid-based polymers in depth 2.3- Scaffold processing 2.4- Basics of
biodegradation of magnesium 2.5- Basics of biodegradation of iron scaffold
Section 3: From bench test to preclinical assessment 3.1- Unlocking scaffold
mechanical properties 3.2- Bench testing for polymeric bioresorbable
scaffolds 3.3- Bench test for magnesium scaffold 3.4- Simulation of flow and
shear stress 3.5- Preclinical assessment of bioresorbable scaffolds and
regulatory implication Section 4: Lesson learned from preclinical assessment
4.1- PLA scaffold 4.2- Iron Section 5: Imaging to evaluate the bioresorbable
scaffold: A corelab perspective, methodology of measurement and assessment
5.1- Quantative coronary angiography of bioresorbable vascular scaffold: a
corelab perspective 5.2- Assessment of bioresorbable scaffolds by IVUS:
echogenicity, virtual histology and palpography 5.3- Optical coherence
tomography analysis vascular scaffold in comparison with metallic stents: a
corelab perspective 5.4- Non-invasive coronary tomography analysis after
bioresorbable scaffold implantation 5.5- Angiography is sufficient 5.6-
Intravascular ultrasound is a must in bioresorbable scaffold implantation
5.7- OCT is the way to go 5.8- Imaging to evaluate the bioresorbable
scaffold. Clinician's perspective: I need both (IVUS and OCT) 5.9- Multislice
computed tomography as a modality of follow-up Section 6: Clinical evidence
of randomised and non-randomised trials: personal perspective 6.1- What are
appropriate clinical endpoints? From device failure assessment to angina
evaluation 6.2- Angina reduction after BRS implantation: correlation with
changes in coronary haemodynamics 6.3- Comparison of everolimus eluting
bioresorbable scaffolds with everolimus eluting metallic stents for treatment
of coronary artery stenosis: Three-year follow-up of the Absorb II randomized
trial 6.4- The ABSORB China trial 6.5- ABSORB Japan 6.6- What have we learned
from meta-analysis of 1 year outcomes with the Absorb bioresorbable scaffold
in patients with coronary heart disease 6.7- Summary of investigator-driven
registries on absorb bioresorbable vascular scaffolds 6.8-
Investigator-driven randomised trials 6.9- The DESolve scaffold 6.10- Results
of clinical trials with BIOTRONIK magnesium scaffolds 6.11- The REVA medical
program: from ReZolve (R) to Fantom (R) 6.12- The Amaranth's bioresorbable
vascular scaffold technology 6.13- The mirage microfiber sirolimus eluting
coronary scaffold 6.14- The Igaki-Tamai stent: the legacy of the work of
Hideo Tamai Section 7: Clinical evidence in specific patient subsets:
personal perspective 7.1- Left main interventions with BRS 7.2- Bioresorbable
scaffolds in bifurcations 7.3- BVS in chronic total occlusions: clinical
evidence, tips and tricks 7.4- Bioresorbable scaffolds in diffuse disease
7.5- Bioresorbable scaffolds in mulitvessel coronary disease 7.6-
Bioresorbable coronary scaffolds in non-St elevation acute coronary syndromes
7.7- Bioresorbable vascular scaffold in ST-segment elevation myocardial
infarction: clinical evidence, tips and tricks 7.8- Bioresorbable scaffolds
for treating coronary artery disease in patients with diabetes mellitus 7.9-
BRS in calcified lesions 7.10- BRS textbook: invasive sealing of vulnerable,
high-risk lesions Section 8: Complications (incidence, diagnosis, potential
mechanisms and treatment) 8.1- Acute and subacute scaffold thrombosis 8.2-
Late and very late scaffold thrombosis 8.3- Treatment of bioresorbable
scaffold failure 8.4- Recoil and bioresorbable scaffolds 8.5- Scaffold
disruption and late discontinuities 8.6- The incidence, potential mechanism
of side-branch occlusion after implantation of bioresorbable scaffold(s):
insights from ABSORB II Section 9: Tips and tricks to implant BRS 9.1- Tips
and tricks for implanting BRS: sizing, pre- and post-dilatation 9.2- Approach
to bifurcation lesions Section 10: Emerging technologies (pre-CE mark,
pre-FA, pre-PMDA and pre-CFDA) 10.1- Overview of the field 10.2- MeRes100
(TM)- a sirolimus eluting bioresorbable vascular scaffold system 10.3-
XINSORB bioresorbable vascular scaffold 10.4- NeoVas (TM) bioresorbable
coronary scaffold system 10.5- ArterioSorb (TM) bioresorbable scaffold by
Arterius Ltd 10.6- Lifetech 10.7- Abbott: new generation absorb scaffold.
Prof. Patrick W. Serruys is a professor of Interventional Cardiology at the Interuniversity Cardiological Institute of the Netherlands (1988-1998), and Erasmus MC. Since 1980 he was a Director of the Clinical Research Program of the Catheterization Laboratory, Thorax Center at Erasmus University, and till April 1st 2014 (retirement date) the Head of the Interventional Department, Thorax Center, Erasmus MC (University Medical Center Rotterdam), Rotterdam, The Netherlands. He is a Fellow of the American College of Cardiology and a Fellow of the European Society of Cardiology and scientific council of the International College of Angiology. In 1996 he received the TCT Career Achievement Award and in 1997 he was awarded the Wenkebach Prize of the Dutch Heart Foundation. In 2000 he was awarded the Gruentzig Award of the European Society of Cardiology. In 2001 he held the Paul Dudley White Lecture at the American Heart Association in the USA. In 2004 he received the Andreas Gruentzig Award of the Swiss Society of Cardiology. In 2005 he held the 4th International Lecture at the AHA and Mikamo Lecture at the Japanese heart Association. In 2006 he received the highest award of the Clinical Council of the American Heart Association: the James Herrick Award. In 2007 he received the Arrigo Recordati International Prize (Italy) and the ICI Achievement Award (bestowed by the President of Israel Shimon Perez). In 2008 he received the Einthoven Penning (Leiden). In 2009 he became Doctor Honoris Causa from the University of Athens. In 2011 he received the Lifetime Achievement Award, bestowed by the American College of Cardiology, in recognition of many years of service and invaluable contributions to the ACC. At the end of 2011 Prof. Serruys received the Ray C. Fish Award, bestowed by the Texas Heart Institute, for outstanding achievement and contribution to cardiovascular medicine. In 2012 he received a Golden Medal of the European Society of Cardiology. In 2013 he became Doctor Honoris Causa from the Complutense University of Madrid.
